Security Snapshot

Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) Institutional Ownership

CUSIP: 747324101

13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

78

Shares (Excl. Options)

30,195,945

Price

$1.15

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
PYXS on Nasdaq
Shares outstanding
62,130,557
Price per share
$1.46
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
30,195,945
Total reported value
$34,729,768
% of total 13F portfolios
0%
Share change
-780,136
Value change
-$6,939,019
Number of holders
78
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 747324101.
  • 78 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 78 to 1 between Q4 2025 and Q1 2026.
  • Reported value moved from $34,729,768 to $1,921.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 78 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 747324101?
CUSIP 747324101 identifies PYXS - Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Sullivan Lara 11% +9.1% $7,844,727 +$955,040 7,543,007 +14% Lara Sullivan, M.D. 31 Mar 2025
Laurion Capital Management LP 7.7% $9,880,747 4,796,479 Laurion Capital Management LP 31 Dec 2025
GordonMD Global Investments LP 6.2% $5,330,289 3,834,740 GordonMD Global Investments LP 14 Jul 2025
INTEGRATED CORE STRATEGIES (US) LLC 4% -26% $2,587,602 -$698,942 2,488,079 -21% Millennium Management LLC 31 Mar 2025
BlackRock, Inc. 1.5% -68% $2,192,635 -$5,718,934 926,805 -72% BlackRock, Inc. 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 1.3% -73% $1,497,185 -$4,985,888 818,134 -77% Millennium Management LLC 30 Sep 2025
Ridgeback Capital Investments L.P. 0.6% $373,600 359,231 Ridgeback Capital Investments L.P. 31 Dec 2024

As of 31 Dec 2025, 78 institutional investors reported holding 30,195,945 shares of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS). This represents 49% of the company’s total 62,130,557 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) together control 46% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Pfizer Inc 11% 7,032,770 0% 3.4% $8,087,685
Laurion Capital Management LP 7.7% 4,796,479 +32% 0.38% $5,515,951
GordonMD Global Investments LP 6.6% 4,121,870 0% 3.4% $4,740,151
VANGUARD GROUP INC 3.8% 2,335,768 +7.9% 0% $2,686,133
Palo Alto Investors LP 1.7% 1,037,421 0% 0.17% $1,193,034
683 Capital Management, LLC 1.4% 891,910 +70% 0.09% $1,025,697
JANE STREET GROUP, LLC 1.3% 786,010 +159% 0% $903,911
BlackRock, Inc. 1.3% 784,077 +15% 0% $901,689
MILLENNIUM MANAGEMENT LLC 1.2% 743,107 -8.9% 0% $854,573
RENAISSANCE TECHNOLOGIES LLC 1.2% 728,380 +26% 0% $837,637
Atle Fund Management AB 0.99% 617,245 0.23% $709,831
BANK OF AMERICA CORP /DE/ 0.95% 587,851 -4.6% 0% $676,029
GEODE CAPITAL MANAGEMENT, LLC 0.93% 577,211 +6% 0% $664,211
Longaeva Partners L.P. 0.81% 503,214 0% 0.07% $578,696
UBS Group AG 0.63% 392,766 +5.1% 0% $451,681
MARSHALL WACE, LLP 0.63% 389,764 0% $448,229
Decheng Capital LLC 0.53% 326,810 0% 0.05% $375,832
ExodusPoint Capital Management, LP 0.51% 317,769 0% $365,434
XTX Topco Ltd 0.47% 289,033 +1533% 0.01% $332,388
CITADEL ADVISORS LLC 0.39% 243,589 -28% 0% $280,127
STATE STREET CORP 0.39% 241,637 +20% 0% $277,883
Point72 Asset Management, L.P. 0.3% 188,136 0% $216,356
Graham Capital Management, L.P. 0.3% 183,942 0.01% $211,533
Bank of New York Mellon Corp 0.27% 165,044 0% 0% $189,800
Qube Research & Technologies Ltd 0.23% 145,813 +373% 0% $167,685

Institutional Holders of Pyxis Oncology, Inc. - Common Stock, par value $0.001 per share (PYXS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,316 $1,921 -$31,390 $1.46 1
2025 Q4 30,195,945 $34,729,768 -$6,939,019 $1.15 78
2025 Q3 26,713,589 $59,287,871 +$123,860 $2.22 72
2025 Q2 27,457,764 $30,197,446 -$2,879,012 $1.10 74
2025 Q1 30,249,732 $29,641,653 -$2,654,672 $0.98 88
2024 Q4 31,554,509 $49,227,444 -$20,797,470 $1.56 97
2024 Q3 27,885,908 $103,378,553 -$998,440 $3.67 91
2024 Q2 28,117,599 $93,075,160 +$16,220,879 $3.31 78
2024 Q1 22,927,678 $97,671,130 +$61,948,310 $4.26 69
2023 Q4 8,795,542 $15,830,945 +$874,420 $1.80 50
2023 Q3 7,757,315 $15,436,473 -$3,354,663 $1.99 49
2023 Q2 9,605,170 $24,586,580 -$3,344,692 $2.56 46
2023 Q1 10,344,999 $41,482,052 -$20,570,227 $4.01 46
2022 Q4 19,762,209 $26,479,807 -$1,331,635 $1.34 31
2022 Q3 19,443,728 $38,301,000 -$1,468,358 $1.97 35
2022 Q2 20,034,321 $47,682,000 -$658,113 $2.38 37
2022 Q1 18,945,997 $76,067,000 -$5,559,229 $4.04 44
2021 Q4 18,338,628 $199,903,000 +$199,792,959 $10.97 51